US-based Kala Pharmaceuticals has begun a Phase II clinical trial of its loteprednol etabonate MPP (LE-MPP) drug product KP-121 in patients with intraretinal or subretinal fluid secondary to retinal vein occlusion (RVO) or diabetic macular edema (DME).

In this trial (KPI-121-C-004), the company will investigate the efficacy and safety of 1% LE-MPP and 0.25% LE-MPP, dosed four times daily in patients having measurable intraretinal or subretinal fluid.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company intends to enrol about 20 patients from two US centres in this single-masked, randomised Phase II trial.

Ophthalmic Consultants of Boston director of vitreoretinal service Jeffery Heier and Retina-Vitreous Associates Medical Group MD David Boyer will serve as the two lead investigators in the exploratory trial.

"Kala is making significant progress toward demonstrating the unique ability of Kala’s MPP platform to deliver drugs to the back of the eye following topical administration."

Kala Pharmaceuticals chief medical officer Kim Brazzell said: "We are excited about the progress of our lead nanotechnology-based programme, LE-MPP, with four active clinical trials.

See Also:

"With the initiation of our latest trial in RVO and DME, Kala is making significant progress toward demonstrating the unique ability of Kala’s MPP platform to deliver drugs to the back of the eye following topical administration."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Additionally, the company has started a Phase II clinical trial (KPI-121-C-003) of LE-MPP in patients with meibomian gland disease (MGD).

In the double-masked, randomised Phase II (KPI-121-C-003) trial of LE-MPP, the company will assess the safety and efficacy of 0.25% LE-MPP compared with vehicle dosed four times daily in subjects with meibomian gland disease.

About 150 patients in up to ten centres in the US will be enrolled in the KPI-121-C-003 trial.

Heier said: "The potential to deliver substantial amounts of drug to tissues in the back of the eye using non-invasive topical administration would represent a significant advance in the treatment of retinal disease.

"Kala has generated promising preclinical data, and we look forward to further evaluating the company’s nanotechnology to determine if it offers potential for a less-invasive treatment for patients."